J Cancer 2020; 11(12):3502-3511. doi:10.7150/jca.42645 This issue


Aberrant expression and regulatory network of splicing factor-SRSF3 in tumors

Yingying Che, Lin Fu

Institute of Chronic Disease, Qingdao Municipal Hospital, Qingdao University, Qingdao 266000, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Che Y, Fu L. Aberrant expression and regulatory network of splicing factor-SRSF3 in tumors. J Cancer 2020; 11(12):3502-3511. doi:10.7150/jca.42645. Available from https://www.jcancer.org/v11p3502.htm

File import instruction


Alternative splicing facilitates the splicing of precursor RNA into different isoforms. Alternatively spliced transcripts often exhibit antagonistic functions or differential temporal or spatial expression patterns. There is increasing evidence that alternative splicing, especially by the serine-arginine rich (SR) protein family, leads to abnormal expression patterns and is closely related to the development of cancer. SRSF3, also known as SRp20, is a splicing factor. Through alternative splicing, it plays important roles in regulating various biological functions, such as cell cycle, cell proliferation, migration and invasion, under pathological and physiological conditions. Deregulation of SRSF3 is an essential feature of cancers. SRSF3 is also considered a candidate therapeutic target. Therefore, the involvement of abnormal splicing in tumorigenesis and the regulation of splicing factors deserve further analysis and discussion. Here, we summarize the function of SRSF3-regulated alternative transcripts in cancer cell biology at different stages of tumor development and the regulation of SRSF3 in tumorigenesis.

Keywords: SRSF3, tumor, alternative splicing, biological functions